TAIPEI, Sept. 27,
2024 /PRNewswire/ -- Anbogen, a clinical-stage
biotech company, today announced a drug supply collaboration to
evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with
BeiGene's anti-PD-1 antibody tislelizumab, in patients with
mismatch repair–proficient (pMMR) or microsatellite stable (MSS)
metastatic colorectal cancer (mCRC) in a global Phase II
trial. Under the terms of the agreement, BeiGene will supply
tislelizumab to Anbogen for the study.
In 2020, over 1.9 million new cases of colorectal cancer were
diagnosed globally. Immune checkpoint inhibitors (ICIs) have
emerged as a primary treatment for metastatic colorectal cancer
(mCRC) with mismatch repair deficiency (dMMR) or high
microsatellite instability (MSI-H). However, this innovative
therapy benefits only a small fraction of patients, as less than 5%
of mCRC cases exhibit dMMR/MSI-H. Consequently, there remains a
significant unmet need for the 95% of patients with pMMR/MSS
tumors, who do not respond to ICIs.
ABT-301, a novel HDAC inhibitor, has shown promising safety and
pharmacokinetic profiles in a prior Phase 1 study as a single
agent. Preclinical studies indicate that ABT-301 enhances the
effectiveness of anti-PD-1/anti-PD-L1 therapies by increasing CD8+
cytotoxic T cells and decreasing monocytic myeloid-derived
suppressor cells within both the tumor and circulation, and
inhibiting angiogenesis. These immune response enhancements may
broaden the efficacy of ICIs in colorectal cancer patients. The
upcoming Phase II study will investigate the effectiveness of
treatment regimens combining ABT-301 and tislelizumab, with and
without Bevacizumab, in pMMR/MSS mCRC patients with significant
unmet needs.
"We are excited to partner with BeiGene to investigate this
promising combination therapy," said John
Hsu, CEO of Anbogen. "ABT-301 has shown potential in
preclinical studies, and we believe that combining it with
tislelizumab could provide a new therapeutic option for patients
with colorectal cancer."
The clinical trial will be conducted in multiple centers and
will evaluate the safety, tolerability, and preliminary efficacy of
the combination therapy in patients with advanced MSS CRC. The
study is expected to begin enrollment in the first quarter of
2025.
About Anbogen
Anbogen is a clinical-stage biotech company that completed a
US$20M Series A in 2024. We are
dedicated to developing precision anti-cancer drugs and are
committed to R&D innovations to improve the lives of cancer
patients around the world. The company was founded by Dr.
Joe Shih in response to national
science and technology policy. The team has years of experience in
new drug development while working at the National Health Research
Institutes and in the biopharma industry.
Currently, there are two clinical-stage assets being developed.
ABT-101 is being investigated in non-small cell lung cancer (NSCLC)
patients who harbor HER2 exon20 insertion mutations, and ABT-301
and being investigated in pMMR/MSS mCRC patients in combination
with anti-PD-1. For more information, please visit
www.anbogen.com.
View original
content:https://www.prnewswire.com/news-releases/anbogen-announces-drug-supply-collaboration-with-beigene-to-evaluate-combination-therapy-in-colorectal-cancer-302258403.html
SOURCE Anbogen Therapeutics